Physician profile
Alex M Goldsmith
NPI 1417907064
$12,460.98
in general payments reported to CMS, 2019-2025
61 companies · $1,579 in 2025
The $1,579 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,484 · 2020: $1,228 · 2021: $2,341 · 2022: $2,095 · 2023: $1,985 · 2024: $1,749 · 2025: $1,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,313.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,118.89 | 2019-2025 | |
| Amgen INC. | $1,067.08 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,048.35 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $806.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $699.53 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $603.36 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $566.55 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $563.84 | 2019-2024 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $466.47 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $451.02 | 2019-2025 | |
| Allergan, INC. | $440.35 | 2019-2020 | |
| Glaxosmithkline, LLC. | $404.74 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $373.16 | 2019-2025 | Xarelto, Spravato |
| Esperion Therapeutics, INC. | $323.95 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.73 | 2019-2025 | Jardiance |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Goldsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.